[JS01] Joint Session 01 (MOU Session): Adult Acute Lymphoblastic Leukemia in Asia
Room 1
March 27 (Thu), 09:00-10:15
Won Sik Lee (Inje University College of Medicine, Korea) Han Viet Trung (Bach Mai Hospital, Vietnam)
09:00-09:15
Opportunities and challenges in managing adult ALL in Vietnam
Han Viet Trung (Bach Mai Hospital, Vietnam)
09:15-09:30
Adult ALL in Armenia
Armine Farmazyan (Hematology Center after Prof. R. H. Yeolyan, Armenia)
09:30-09:45
Clinical features, genetic profiling and treatment outcomes of adult acute lymphoblastic leukemia: A prospective multicenter study in Thailand
Weerapat Owattanapanich (Faculty of Siriraj Hospital, Mahidol University, Thailand)
09:45-10:00
Adult ALL in Korea
Ik Chan Song (Chungnam National University College of Medicine, Korea)
10:00-10:15
Discussion
Hye Lim Jung (Sungkyunkwan University School of Medicine, Korea) Kyung-Ha Ryu (Ewha Womans University College of Medicine, Korea)
09:00-09:25
Diagnosis and treatment of Ph-like ALL in children and young adults
Thai Hoa Tran (Université de Montréal, Canada)
09:25-09:50
Advances in the genetics of down syndrome-related myeloid leukemia
Etsuro Ito (Hirosaki University Graduate School of Medicine, Japan)
09:50-10:15
Towards improving outcomes for high risk pediatric acute myeloid leukemia
Todd Cooper (Seattle Children’s Hospital Cancer and Blood Disorders Service, USA)
[SS02] Scientific Session 02: Overcoming the resistance mechanisms of Multiple Myeloma
Room 3
March 27 (Thu), 09:00-10:15
Kihyun Kim (Sungkyunkwan University School of Medicine, Korea) Chang-Ki Min (College of Medicine, The Catholic University of Korea, Korea)
09:00-09:25
Immune therapy and the bone marrow microenvironment in multiple myeloma
Hearn Jay Cho (Icahn School of Medicine at Mount Sinai, USA)
09:25-09:50
Mechanisms of antigen escape after T-cell based immunotherapies
Paola Neri (University of Calgary, Canada)
09:50-10:15
Cellular immunotherapy platforms in multiple myeloma
Sung-Hoon Jung (Chonnam National University Medical School, Korea)
[ES01] Education Session 01: Understanding the fundamentals of Myelodysplastic Syndrome KORRoom 4
March 27 (Thu), 09:00-10:15
Yoo Jin Kim (College of Medicine, The Catholic University of Korea, Korea) Yong Park (Korea University College of Medicine, Korea)
09:00-09:25
Tracing the changes: MDS risk stratification
Seo-Yeon Ahn (Chonnam National University Medical School, Korea)
09:25-09:50
Managing MDS with HMAs following the AZA-001 trial
Silvia Park (College of Medicine, The Catholic University of Korea, Korea)
09:50-10:15
Approved MDS treatments beyond HMAs
Junshik Hong (Seoul National University College of Medicine, Korea)
[PL01] Plenary Lecture 01
Room 1+2
March 27 (Thu), 10:30-11:15
Chul Won Jung (Sungkyunkwan University School of Medicine, Korea)
10:30-11:15
Myeloproliferative Neoplasms: 2025 update
Ayalew Tefferi (Mayo Clinic, USA)
[PS01] Presidential Symposium 01
Room 1+2
March 27 (Thu), 11:15-12:00
Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)
11:15-12:00
CAR T-cell therapy for Lymphomas: Current and future trends
Sattva S Neelapu (The University of Texas MD Anderson Cancer Center, USA)
[SY01] Satellite Symposium 01: Handok Inc.
Room 1
March 27 (Thu), 12:15-13:05
Je-Hwan Lee (University of Ulsan College of Medicine, Korea)
12:15-13:05
Expanding horizons in PNH treatment: Pegcetacoplan in proximal inhibition
Silvia Park (College of Medicine, The Catholic University of Korea, Korea)
[SY02] Satellite Symposium 02: ROCHE KOREA
Room 2
March 27 (Thu), 12:15-13:05
Deok Hwan Yang (Chonnam National University Medical School, Korea)
12:15-13:05
Recent insights on DLBCL treatment: focused on glofitamab and polatuzumab
Andrew Davies (University of Southampton, UK)
[SY03] Satellite Symposium 03: BMS Pharmaceutical Korea
Room 3
March 27 (Thu), 12:15-13:05
Jin Seok Kim (Yonsei University College of Medicine, Korea)
12:15-13:05
Optimizing current treatment strategies in relapsed/refractory multiple myeloma
Wee Joo Chng (National University of Singapore, Singapore)
Dong-Yeop Shin (Seoul National University College of Medicine, Korea) Hyeon Jin Park (National Cancer Center, Korea)
13:55-14:07
Intensity-adjusted salvage chemotherapy plus FLT3-inhibitor gilteritinib in relapsed/refractory acute myeloid leukemia with mutated FLT3-ITD/TKD (SAPPHIRE-G)
Hawk Kim (Gachon University College of Medicine, Korea)
14:07-14:19
Deciphering clinical and genetic aspects of TP53-mutated acute myeloid leukemia
Songyi Park (Seoul National University Boramae Medical Center, Korea)
14:19-14:31
Functional characteristics and clinical implications of CD39-expressing T Cell populations in patients with newly diagnosed acute myeloid leukemia
Nayeon Seong (Korea University College of Medicine, Korea)
14:31-14:43
Genetic prognostic factors in pediatric core binding factor acute myeloid leukemia
Jae Wook Lee (College of Medicine, The Catholic University of Korea, Korea)
14:43-14:55
The efficacy of hypomethylating agent and venetoclax treatment for secondary acute myeloid leukemia patients evolving from myelodysplastic syndrome or chronic myelomocytic leukemia
PilYong Lim (College of Medicine, The Catholic University of Korea, Korea)
14:55-15:07
Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: a multicenter study of TROPHY Group
Yi Xia (Peking University People's Hospital, China)
Sun-Young Kong (National Cancer Center, Korea) Jaewoo Song (Yonsei University College of Medicine, Korea)
13:55-14:07
Representativeness of clone size measured by using NGS-based immunoglobulin gene rearrangement test in comparison to flow cytometry in multiple myeloma
Hyeseong Ryu (University of Ulsan College of Medicine, Korea)
14:07-14:19
Evaluation of two NGS-based somatic hypermutation detection assay in chronic lymphocytic leukemia
Yehyun Kang (Yonsei University College of Medicine, Korea)
14:19-14:31
Development of amplicon-based NGS assay for detection of BCR::ABL1 kinase domain mutation
TaekGyu Lee (Yonsei University College of Medicine, Korea)
14:31-14:43
Spectrum of TP53 mutation in hematologic malignancies
Seo Yoon Jang (Seoul National University Hospital, Korea)
14:43-14:55
An NGS-based analysis of the genomic landscapes of beta-globin gene cluster, the beta-LCR, and HbF modifiers yields new phenotype regulators and diagnostic data on symptomatic beta-thalassemia
Prashant Sharma (Postgraduate Institute of Medical Education and Research, India)
14:55-15:07
NG2 expression pattern and its predictive value for different types of KMT2A translocations in acute myeloid leukemia and B acute lymphoblastic leukemia
Sweta Rajpal (Tata Memorial Centre, India)
[OP03] Oral Presentation 03: Lymphoma
Room 3
March 27 (Thu), 13:55-15:10
Jeong-Ok Lee (Seoul National University College of Medicine, Korea) Seong Hyun Jeong (Ajou University School of Medicine, Korea)
13:55-14:07
Bendamustine-Rituximab (R-benda) in first-line treatment for advanced stage follicular lymphoma presented better clinical outcomes compared to other Rituximab-based regimen
Gi June Min (College of Medicine, The Catholic University of Korea, Korea)
14:07-14:19
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide followed by autologous stem cell transplantation in patients with primary or secondary central nervous system lymphoma
Dong Hyun Kim (Seoul National University College of Medicine, Korea)
14:19-14:31
Treatment patterns and survival outcomes in patients with mantle cell lymphoma: Interim report of the Asia-Pacific multinational prospective registry study
Hyungwoo Cho (University of Ulsan College of Medicine, Korea)
14:31-14:43
Exploring microbiome analysis as the predictive marker of treatment resistance in relapsed/refractory diffuse large B cell lymphoma patients treated with CD19 CAR-T cell therapies
Sang Eun Yoon (Sungkyunkwan University School of Medicine, Korea)
14:43-14:55
Seven-Year overall survival from ECHELON-1: A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin Lymphoma
Won Seog Kim (Sungkyunkwan University School of Medicine, Korea)
14:55-15:07
Allogeneic versus autologous hematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: a real-world multicenter analysis in China
Yuewen Wang (Peking University People's Hospital, China)
Jun Eun Park (Korea University College of Medicine, Korea) Joon Seong Park (Ajou University School of Medicine, Korea)
13:55-14:07
Asciminib provides better efficacy and favorable safety and tolerability Vs investigator-selected tyrosine kinase inhibitors in newly diagnosed chronic myeloid leukemia: Results from the ASC4FIRST study East Asian subgroup
Sung-Eun Lee (College of Medicine, The Catholic University of Korea, Korea)
14:07-14:19
Clinical outcomes in patients with myelodysplastic syndromes carrying the Germline DDX41 mutation
Hohyung Nam (College of Medicine, The Catholic University of Korea, Korea)
14:19-14:31
Ropeginterferon in low-risk patients with Polycythemia vera
Ji Yun Lee (Seoul National University College of Medicine, Korea)
14:31-14:43
The clinical diagnostic value of neutrophilto-lymphocyte ratio in patients with erythrocytosis
Seug Yun Yoon (Soonchunhyang University College of Medicine, Korea)
14:43-14:55
Novel genetic aberrations in chronic myeloid leukemia in adolescents and young adults
Priyavadhana Balasubramanian (All India Institute of Medical Sciences, India)
14:55-15:07
An insight into treatment free remission (TFR) outcomes in chronic myeloid leukaemia (CML) - A tertiary centre experience in Malaysia
Christopher Chin Keong Liam (Hospital Sultanah Aminah, Malaysia)
[JS02] Joint Session 02 (EHA-KSH): Acute Myeloid Leukemia - Research and practice
Room 1
March 27 (Thu), 15:25-16:40
Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea) Brian Huntly (University of Cambridge, UK)
15:25-15:40
Altered transcriptional programmes in AML: The role of aberrant gene regulatory complexes (GRC)
Brian Huntly (University of Cambridge, UK)
15:40-15:55
Treatment of AML in Korea
June-Won Cheong (Yonsei University College of Medicine, Korea)
15:55-16:10
Genetics guiding treatment in AML
Hartmut Döhner (Ulm University Hospital, Germany)
16:10-16:25
The dynamic landscape of AML genetics: From the perspective of the Korean AML/MDS working party study
Jae-Sook Ahn (Chonnam National University Medical School, Korea)
16:25-16:40
Discussion
Soo-Mee Bang (Seoul National University College of Medicine, Korea) Sung Hwa Bae (Daegu Catholic University School of Medicine, Korea)
15:25-15:50
Advances in the treatment of cancer-associated thrombosis
Jeffrey I. Weitz (McMaster University, Canada)
15:50-16:15
Managing patients with cancer associated venous thromboembolism
Robert D. McBane II (Mayo College of Medicine, USA)
16:15-16:40
Risk assessment and thromboprophylaxis for cancer-associated VTE
Ingrid Pabinger-Fasching (Medical University of Vienna, Austria)
[SS04] Scientific Session 04: Advancements in Peripheral T-cell Lymphoma: From biological insights to innovative treatments
Room 3
March 27 (Thu), 15:25-16:40
Jae Yong Kwak (Jeonbuk National University Medical School, Korea) Deok Hwan Yang (Chonnam National University Medical School, Korea)
15:25-15:50
Turning the corner in the management of the PTCL
Owen A O'Connor (University of Virginia Comprehensive Cancer Center, USA)
15:50-16:15
Recent updates and future in the management of R/R PTCL
Won Seog Kim (Sungkyunkwan University School of Medicine, Korea)
16:15-16:40
The development of new agents in T-cell lymphoma
Hyun Jung Lee (Kyung Hee University College of Medicine, Korea)
[ES02] Education Session 02: Basic understanding and application of Artificial Intelligence KORRoom 4
March 27 (Thu), 15:25-16:40
Hyery Kim (University of Ulsan College of Medicine, Korea) Joon Ho Moon (Kyungpook National University School of Medicine, Korea)
15:25-15:50
AI everywhere
Auk Kim (Department of Computer Science and Engineering, Kangwon National University, Korea)
15:50-16:15
Revolutionizing medical documentation: Leveraging ChatGPT and RAG frameworks for optimized scientific writing and clinical interpretation
Sang-Hyun Hwang (University of Ulsan College of Medicine, Korea)
16:15-16:40
Generative AI use case for medical research: HRS (Healthcare data research suite)
Soo-Yong Shin (Head of Research & Chief Privacy Officer, KakaoHealthcare, Korea)
[SS05] Scientific Session 05: Red blood cells in Myeloproliferative Neoplasm
Room 1
March 27 (Thu), 16:55-18:10
Sung-Yong Kim (Konkuk University School of Medicine, Korea) Jong Ho Won (Soonchunhyang University College of Medicine, Korea)
16:55-17:20
Iron metabolism in JAK2-mutant myeloproliferative neoplasms
Radek C. Skoda (Dan L Duncan Comprehensive Cancer Center, USA)
17:20-17:45
Hepcidin in the pathophysiology of and as treatment for polycythemia vera
Yelena Z. Ginzburg (Icahn School of Medicine at Mount Sinai, USA)
17:45-18:10
Anemia and JAK inhibitors
Jean-Jaques Kiladjian (Hôpital Saint-Louis, France)
[SS06] Scientific Session 06: Advances and challenges in Histiocytic diseases: A comprehensive update
Room 2
March 27 (Thu), 16:55-18:10
Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea) Ho Joon Im (University of Ulsan College of Medicine, Korea)
16:55-17:20
Innovations in HLH therapy: Beyond HLH94
Michelle Hermiston (VinUniversity, Vietnam / UCSF, USA)
17:20-17:45
Navigating pediatric histiocytosis: Advances in first-line MAPK inhibition and targeted therapies
Oussama Abla (The Hospital for Sick Children, Canada)
17:45-18:10
From CRS to IEC-HS: Advancements in understanding and treating hemophagocytic syndromes
Melissa Hines (St. Jude Children’s Research Hospital, USA)
[SS07] Scientific Session 07: Breaking new ground in Acute Myeloid Leukemia
Room 3
March 27 (Thu), 16:55-18:10
Je-Hwan Lee (University of Ulsan College of Medicine, Korea) June-Won Cheong (Yonsei University College of Medicine, Korea)
16:55-17:20
Understanding and overcoming resistance in AML
Dong-Yeop Shin (Seoul National University College of Medicine, Korea)
17:20-17:45
Exploring Immune checkpoint targets beyond PD-1 and PD-L1 in AML (LAIR-1 agonism as a novel therapy for acute myeloid leukemia)
Tae Kon Kim (Vanderbilt University Medical Center, USA)
17:45-18:10
Implementing a functional precision medicine for AML patients
Mika Kontro (Helsinki University Hospital, Finland)
[ES03] Education Session 03: Turning ideas into successful Clinical Trial: A practical approach KORRoom 4
March 27 (Thu), 16:55-18:10
Dok Hyun Yoon (University of Ulsan College of Medicine, Korea) Hyeon-Seok Eom (National Cancer Center, Korea)
16:55-17:20
Crafting a successful investigator-initiated study proposal: Key elements and strategies
Young Woo Jeon (College of Medicine, The Catholic University of Korea, Korea)
17:20-17:45
Current Trends of Big Data Research Using the Korean National Health Information Database
Kyungdo Han (Department of Statistics and Actuarial Science, Soongsil University, Korea)
17:45-18:10
Phase-specific strategies for adverse events management in clinical trials: Best practices in AE documentation and reporting
Jeong-Ok Lee (Seoul National University College of Medicine, Korea)
March 28 (Friday)
[JS03] Joint Session 03 (ASH-KSH): Chronic Myeloid Leukemia - Era of Next-Generation Sequencing
Room 1
March 28 (Fri), 09:00-10:15
Hawk Kim (Gachon University College of Medicine, Korea) Richard A. Van Etten (University of California, Irvine, USA)
09:00-09:15
Beyond BCR::ABL1 - The role of genomic analysis in the management of CML
Susan Branford (Centre for Cancer Biology, SA Pathology, Australia)
09:15-09:30
Next-Generation Sequencing (NGS) in CML
Jieun Kim (Soonchunhyang University College of Medicine, Korea)
09:30-09:45
What systems biology and AI can teach us about the pathogenesis and therapy of CML
Richard A. Van Etten (University of California, Irvine, USA)
09:45-10:00
Beyond BCR::ABL1 RQ-PCR in CML
Hawk Kim (Gachon University College of Medicine, Korea)
10:00-10:15
Discussion
[SS08] Scientific Session 08: TP53 alterations in hematological malignancy: From clonal hematopoiesis to acute leukemia
Room 2
March 28 (Fri), 09:00-10:15
Sung-Hyun Kim (Dong-A University College of Medicine, Korea) Yoon Hwan Chang (Seoul National University College of Medicine, Korea)
09:00-09:25
Chronic inflammation as a driver of TP53-mutant leukemic evolution
Yan Liu (Northwestern University Feinberg School of Medicine, USA)
09:25-09:50
TP53 copy number and protein expression for risk stratification in AML
Joseph D. Khoury (University of Nebraska Medical Center, USA)
09:50-10:15
Molecular characterization of TP53 mutation in AML and high-risk MDS
Peter J.M. Valk (Erasmus University Medical Center, The Netherlands)
[SS09] Scientific Session 09: Advancing the paradigm in Adult Acute Lymphoblastic Leukemia care
Room 3
March 28 (Fri), 09:00-10:15
Seok Lee (Ewha Womans University College of Medicine, Korea) Ho-Young Yhim (Jeonbuk National University Medical School, Korea)
09:00-09:25
Advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: The emerging role of ponatinib and the shift away from allogeneic hematopoietic stem cell transplantation
Jae-ho Yoon (College of Medicine, The Catholic University of Korea, Korea)
09:25-09:50
CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia
Jae Park (Memorial Sloan Kettering Cancer Center, USA)
09:50-10:15
Navigating new horizons: Safety and efficacy of CD7-CAR-T cells in T-ALL/LBL
Yongxian Hu (The First Affiliated Hospital of College of Medicine, Zhejiang University, China)
Sangkyun Sohn (Kyungpook National University School of Medicine, Korea) Myungshin Kim (College of Medicine, The Catholic University of Korea, Korea)
09:00-09:25
MRD-based therapeutic decisions in AML
Dae Hun Kwag (College of Medicine, The Catholic University of Korea, Korea)
09:25-09:50
MRD-based therapeutic decisions in pediatric ALL
Jung Yoon Choi (Seoul National University College of Medicine, Korea)
09:50-10:15
MRD-based therapeutic decisions in MM
Ji Hyun Lee (Dong-A University College of Medicine, Korea)
[PL02] Plenary Lecture 02
Room 1+2
March 28 (Fri), 10:30-11:15
Sung-Soo Yoon (Seoul National University College of Medicine, Korea)
10:30-11:15
From ancient origins to modern tools: CD38's evolutionary legacy in science and clinical practice
Fabio Malavasi (University of Torino, Italy)
Dok Hyun Yoon (University of Ulsan College of Medicine, Korea)
12:15-13:05
Immunoglobulin therapy in lymphoma patients undergoing SCT and CAR T-therapy
Gi June Min (College of Medicine, The Catholic University of Korea, Korea)
[SY06] Satellite Symposium 06: Johnson & Johnson Innovative Medicine
Room 2
March 28 (Fri), 12:15-13:05
Won Seog Kim (Sungkyunkwan University School of Medicine, Korea)
12:15-13:05
Reshaping Mantle Cell Lymphoma Treatment: Evidence from the TRIANGLE and SYMPATICO Studies
Gyeong-Won Lee (Gyeongsang National University College of Medicine, Korea)
[SY07] Satellite Symposium 07: DKSH KOREA
Room 3
March 28 (Fri), 12:15-13:05
Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)
12:15-13:05
Romiplostim across the spectrum: A comprehensive analysis from ITP management to aplastic anemia treatment
Young Hoon Park (Ewha Womans University College of Medicine, Korea)
[SY08] Satellite Symposium 08: AbbVie Korea
Room 4
March 28 (Fri), 12:15-13:05
Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)
12:15-13:05
Real-world evidence on how to use Epcoritamab in 3L+ DLBCL
Georg Lenz (Munster University Hospital, Germany)
[SY09] Satellite Symposium 09: Novartis Korea
Room 5
March 28 (Fri), 12:15-13:05
Dong-Wook Kim (Eulji University School of Medicine, Korea)
12:15-13:05
Scemblix experience in post 2 TKI setting and the newly diagnosed setting
Michael J. Mauro (Memorial Sloan Kettering Cancer Center, USA)
Jeong A Kim (College of Medicine, The Catholic University of Korea, Korea) Kyung-Nam Koh (University of Ulsan College of Medicine, Korea)
13:35-13:47
Long-term treatment outcome of blinatumomab in adult patients with relapse or refractory acute lymphoblastic leukemia regarding predictive factors including lymphocyte kinetics for response and survival
Seonghan Lee (College of Medicine, The Catholic University of Korea, Korea)
13:47-13:59
Characteristics and treatment outcome of extramedullary relapse involving central nervous system after allogeneic hematopoietic cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Jae-ho Yoon (College of Medicine, The Catholic University of Korea, Korea)
13:59-14:11
Poor prognostic impact of TP53 mutation in association with CDKN2 and IKZF1 gene deletions in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia
Seung-Hwan Lee (College of Medicine, The Catholic University of Korea, Korea)
14:11-14:23
Comparison of measurable residual disease results in adults with B-cell acute lymphoblastic leukemia according to the detection methods: Flow cytometry, NGS, and qPCR
Jae-ho Yoon (College of Medicine, The Catholic University of Korea, Korea)
14:23-14:35
Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including three cases of MEF2D::DAZAP1 and a novel MEF2D-rearrangement
Senlin Zhang (Children’s Hospital of Soochow University, China)
14:35-14:47
Role of circulating immune cell signature in the persistence of measurable residual disease in adult B-Cell lymphoblastic leukemia
Shraddha Mohanty (Advanced Centre for Treatment Research & Education in Cancer, Tata Memorial Centre, India)
[OP06] Oral Presentation 06: Others
Room 2
March 28 (Fri), 13:35-14:50
Jung Woo Han (Yonsei University College of Medicine, Korea) Sung-Eun Lee (College of Medicine, The Catholic University of Korea, Korea)
13:35-13:47
Comparison of eltrombopag vs romiplostim as salvage treatment in patients with relapsed/refractory aplastic anemia
Kyoung Il Min (College of Medicine, The Catholic University of Korea, Korea)
13:47-13:59
Eculizumab for transplant-associated thrombotic microangiopathy: A single-center pediatric experience
Hyun Jin Park (Seoul National University College of Medicine, Korea)
13:59-14:11
Investigating the first venous thromboembolism and recurrence pattern in inherited thrombophilia
Sang-A Kim (Seoul National University College of Medicine, Korea)
14:11-14:23
Letermovir prophylaxis for cytomegalovirus in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation
Qingwei Wang (Children's Hospital of Soochow University, China)
14:23-14:35
Clinical features and prognostic factors of adult systemic chronic active Epstein-Barr Virus Disease: A retrospective analysis using Japanese registry data
Hiroshi Yasui (St. Marianna University School of Medicine, Japan)
14:35-14:47
Clinical characteristics, genetic profiling, and outcomes of 108 patients with chronic myelomonocytic leukemia in a Southeast Asian country
Tarinee Rungjirajittranon (Faculty of Medicine Siriraj Hospital, Thailand)
Min Kyoung Kim (Yeungnam University College of Medicine, Korea) Ho Sup Lee (Kosin University College of Medicine, Korea)
13:35-13:47
Simulation-Based comparative pharmacokinetic and pharmacodynamic analysis in real-world setting in Korean multiple myeloma patients: Influence of demographic and ethnic differences [CAREMM-2109 study]
Suein Choi (College of Medicine, The Catholic University of Korea, Korea)
13:47-13:59
Molecular abnormalities in Waldenstrom’s macroglobulinemia patients treated with rituximab, bortezomib, lenalidomide and dexamethasone: Whole exome sequencing analysis in KMM1803 study
Ga-Young Song (Chonnam National University Medical School, Korea)
13:59-14:11
Toxicity-related treatment cessation in newly diagnosed multiple myeloma - risk factors and survival: An analysis from the APAC and ANZ myeloma and related diseases registry
Ji Hyun Lee (Dong-A University College of Medicine, Korea)
14:11-14:23
A phase II clinical study for evaluating the efficacy and safety of daratumumab, lenalidomide, bortezomib, and dexamethasone in transplantation-eligible elderly patients with newly diagnosed multiple myeloma (KMM2101)
Kihyun Kim (Sungkyunkwan University School of Medicine, Korea)
14:23-14:35
Korean multicenter real-world reports of patients with AL amyloidosis
Sung-Soo Park (College of Medicine, The Catholic University of Korea, Korea)
14:35-14:47
The burden of circulating tumor plasma cells is associated with quantity of mesenchymal stromal cells and CXCR4-expressing plasma cells in bone marrow of newly diagnosed multiple myeloma
Aravind Radhakrishnan (Post Graduate Institute of medical education and Research, India)
Byung Su Kim (College of Medicine, The Catholic University of Korea, Korea) Jae Wook Lee (College of Medicine, The Catholic University of Korea, Korea)
13:35-13:47
Enhanced efficacy and durability of AT101, a novel Anti-CD19 CAR-T: Follow-Up results from the phase 1 Study in patients with relapsed or refractory (r/r) B-Cell non-Hodgkin Lymphoma
Hyungwoo Cho (University of Ulsan College of Medicine, Korea)
13:47-13:59
Proteomic signatures and early predictive biomarkers of veno-occlusive disease in pediatric patients undergoing haploidentical HSCT with busulfan-based conditioning and post-transplant cyclophosphamide
Kyung Taek Hong (Seoul National University College of Medicine, Korea)
13:59-14:11
T Cell profiling using LDA in pediatric haploidentical transplantation
Hyery Kim (University of Ulsan College of Medicine, Korea)
14:11-14:23
BCMA-specific T cell receptor (TCR)-T cells as a potential immunotherapy to treat patients with multiple myeloma
Jooeun Bae (Dana-Farber Cancer Institute, USA)
14:23-14:35
Study on immune haemolytic disease antibodies after haematopoietic stem cell transplantation
Jianyun Liao (Nanfang-Chunfu Children’s Institute of Hematology & Oncology, China)
14:35-14:47
The treatment efficacy and complications of allogeneic hematopoietic stem cell transplantation in children with inborn errors of immunity
Hui Zhang (Children’s Hospital of Soochow University, China)
Hyo Jung Kim (Hallym University College of Medicine, Korea) Ho-Jin Shin (Pusan National University School of Medicine, Korea)
15:05-15:30
Treatment strategies for transplant-eligible newly diagnosed multiple myeloma
Ja Min Byun (Seoul National University College of Medicine, Korea)
15:30-15:55
Treatment of transplant-ineligible Multiple Myeloma
Jongheon Jung (National Cancer Center, Korea)
15:55-16:20
Supportive care of multiple myeloma patients in the new agent era: Optimizing outcomes beyond therapy
Sung-Soo Park (College of Medicine, The Catholic University of Korea, Korea)
[SS10] Scientific Session 10: Next steps toward enhanced treatment for Pediatric Lymphoid malignancies
Room 2
March 28 (Fri), 15:05-16:20
Hyoung Jin Kang (Seoul National University College of Medicine, Korea) Keon Hee Yoo (Sungkyunkwan University School of Medicine, Korea)
15:05-15:30
Overcoming aggressive pediatric non-hodgkin lymphoma
Birgit Burkhardt (University Hospital Münster, Germany)
15:30-15:55
Utilizing NGS MRD as an effective tool in ALL management
Yongmin Tang (Children’s Hospital of Zhejiang University School of Medicine, China)
15:55-16:20
CAEBV, from basic to updated therapeutic options
Seung Min Hahn (Yonsei University College of Medicine, Korea)
[SS11] Scientific Session 11: Driving the future of our CAR
Room 3
March 28 (Fri), 15:05-16:20
Je-Jung Lee (Chonnam National University Medical School, Korea) Seok-Goo Cho (College of Medicine, The Catholic University of Korea, Korea)
15:05-15:30
Current status of "off-the-shelf" allogeneic CAR in the treatment of acute lymphoblastic leukemia
Reuben Benjamin (King’s College London, UK)
15:30-15:55
Allogeneic CAR-T cells engineered with gene-editing strategies for the treatment of B-cell non-Hodgkin lymphomas
Boyu Hu (University of Utah, USA)
15:55-16:20
Memory-like NK cells armed with a neoantigen-specific CAR
Rizwan Romee (Harvard Medical School, USA)
[ES06] Education Session 06: Patient care in Cytopenia consultations: Best practices for hematologists KORRoom 4
March 28 (Fri), 15:05-16:20
Deog-Yeon Jo (Chungnam National University College of Medicine, Korea) Chul Won Choi (Korea University College of Medicine, Korea)
15:05-15:30
Anemia
Eun sang Yu (Korea University College of Medicine, Korea)
15:30-15:55
Thrombocytopenia
Yoo Jin Lee (Ulsan University Hospital, Korea)
15:55-16:20
Neutropenia
Seonggyu Byeon (Gachon University College of Medicine, Korea)
[JS04] Joint Session 04 (Asia Session): Dawn of CAR-T therapy: Asian perspective
Room 1
March 28 (Fri), 16:35-17:50
Won Seog Kim (Sungkyunkwan University School of Medicine, Korea) William YK Hwang (National Cancer Centre Singapore, Singapore)
16:35-16:50
Current status of CAR-T treatment in Taiwan
Tai-Chung Huang (National Taiwan University Hospital, Taiwan)
16:50-17:05
Challenges and opportunities in CAR-T treatment in Singapore
William YK Hwang (National Cancer Centre Singapore, Singapore)
17:05-17:20
Developments of CAR-T cell therapy for multiple myeloma in China
Kailin Xu (The Affiliated Hospital of Xuzhou Medical University, China)
17:20-17:35
Present and future of CAR-T therapy in Korea
Dok Hyun Yoon (University of Ulsan College of Medicine, Korea)
17:35-17:50
Discussion
Myung Geun Shin (Chonnam National University Medical School, Korea) Seongsoo Jang (University of Ulsan College of Medicine, Korea)
16:35-17:00
Minimal (measurable) disease in hematologic malignancy
James L. Zehnder (Stanford University School of Medicine, USA)
17:00-17:25
Exploring the transcriptional and protein landscape of immune cells with CITE-seq
Jennifer A. Foltz (Washington University School of Medicine, USA)
17:25-17:50
Comprehensive resistance profiling of ABL1 variants against various kinase inhibitors using prime editing
Hyongbum Henry Kim (Yonsei University College of Medicine, Korea)
[SS13] Scientific Session 13: Innovations in aplastic anemia and Paroxysmal Nocturnal Hemoglobinuria
Room 3
March 28 (Fri), 16:35-17:50
Hoon Kook (Chonnam National University Medical School, Korea) Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)
16:35-17:00
Finding a better immunosuppressive treatment in SAA
Fengkui Zhang (Chinese Academy of Medical Sciences and Peking Union Medical College, China)
17:00-17:25
Alternative donor HSCT in SAA
Ho Joon Im (University of Ulsan College of Medicine, Korea)
17:25-17:50
Optimal treatment of PNH in the era of proximal complement inhibitors
Rosario Notaro (Core Research Laboratory, ISPRO, Italy)
Ki Seong Eom (College of Medicine, The Catholic University of Korea, Korea) Hyewon Lee (National Cancer Center, Korea)
16:35-17:00
Immunotherapy in follicular lymphoma
Gi June Min (College of Medicine, The Catholic University of Korea, Korea)
17:00-17:25
BTK inhibitions in Waldenström’s macroglobulinemia
Myung-won Lee (Chungnam National University College of Medicine, Korea)
17:25-17:50
Treatment for older patients with Hodgkin lymphoma
Hyunsoo Cho (Yonsei University College of Medicine, Korea)
March 29 (Saturday)
[JS05] Joint Session 05 (Asia Session): MRD and Immunotherapy in Multiple Myeloma: Collaborative insights from Korea and Japan
Room 1
March 29 (Sat), 09:00-10:15
Jin Seok Kim (Yonsei University College of Medicine, Korea) Hiroyuki Takamatsu (Kanazawa University, Japan)
09:00-09:15
Current status of MRD assessment in Japan
Hiroyuki Takamatsu (Kanazawa University, Japan)
09:15-09:30
Current status of MRD assessment in Korea
Saeam Shin (Yonsei University College of Medicine, Korea)
09:30-09:45
Advances in the treatment for RRMM using CAR-T and bispecific antibodies
Tadao Ishida (Japanese Red Cross Medical Center, Japan)
09:45-10:00
Real-world efficacy and safety of teclistamab for patients with released or refractory multiple myeloma: Korean, nationwide, retrospective analysis
Jun Ho Yi (Chung-Ang University College of Medicine, Korea)
10:00-10:15
Discussion
Jeong Yeal Ahn (Gachon University College of Medicine, Korea) Hyun Kyung Kim (Seoul National University College of Medicine, Korea)
09:00-09:25
Investigative approaches to unexplained bleeding
Alessandro Casini (University Hospitals of Geneva, Switzerland)
09:25-09:50
Optimal testing strategies for suspected platelet disorders
Christopher Ward (University of Sydney, Australia)
09:50-10:15
Thrombophilia testing in clinical practice: Indications, challenges, and current approaches
Hee-Jin Kim (Sungkyunkwan University School of Medicine, Korea)
[SS15] Scientific Session 15: Immunotherapy in B-Cell Lymphoma: Current status and emerging approaches
Room 3
March 29 (Sat), 09:00-10:15
Gyeong-Won Lee (Gyeongsang National University College of Medicine, Korea) Yoon Seok Choi (Korea University College of Medicine, Korea)
09:00-09:25
Advancing CD3xCD20 bispecific Abs: Integration in first-line treatment of DLBCL
Catherine Thieblemont (Hôpital Saint-Louis, France)
09:25-09:50
Antibody based treatments for B-cell Lymphoma: New targets and future directions
Youngil Koh (Seoul National University College of Medicine, Korea)
09:50-10:15
Management of toxicity of bispecific antibody for B-cell lymphomas
Koji Izutsu (National Cancer Center Hospital, Japan)
[ES08] Education Session 08: Supportive care: Management of infections and iron overload KORRoom 4
March 29 (Sat), 09:00-10:15
Byong Soo Kim (Korea University College of Medicine, Korea) Yeung-Chul Mun (Ewha Womans University College of Medicine, Korea)
09:00-09:25
Invasive fungal infections in hematologic disease: Prophylaxis and treatment
Sung-Yeon Cho (College of Medicine, The Catholic University of Korea, Korea)
09:25-09:50
CMV infections after HSCT: Prophylaxis and treatment
Haerim Chung (Yonsei University College of Medicine, Korea)
09:50-10:15
Iron overload and iron chelation therapy
Ga-Young Song (Chonnam National University Medical School, Korea)
[PL03] Plenary Lecture 03
Room 1+2
March 29 (Sat), 10:30-11:15
Dong-Wook Kim (Eulji University School of Medicine, Korea)
10:30-11:15
New discoveries that will shape future therapies in Chronic Myeloid Leukemia
Timothy Hughes (South Australian Health and Medical Research Institute (SAHMRI), Australia)
